gadoteridol (prohance) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance. Gadoteridol is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The relatively large magnetic moment produced by the paramagnetic agent results in a relatively large local magnetic field, which can enhance the relaxation rates of water protons in the vicinity of the paramagnetic agent. In magnetic resonance imaging (MRI), visualization of normal and pathologic brain tissue depends in part on variations in the radiofrequency signal intensity that occur with 1) differences in proton density; 2) differences of the spin-lattice or longitudinal relaxation times (T1); and 3) differences in the spin-spin or transverse relaxation time (T2). When placed in a magnetic field, gadoteridol decreases T1 relaxation times in the target tissues. At recommended doses, the effect is observed with greatest sensitivity in the T1-weighted sequences. Gadoteridol does not cross the intact blood-brain barrier and, therefore, does not accumulate in normal brain or in lesions that have a normal blood-brain barrier, e.g., cysts, mature post-operative scars, etc. However, disruption of the blood-brain barrier or abnormal vascularity allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts. The pharmacokinetics of ProHance in various lesions is not known.   NCATS

Chemistry

  • SMILES: [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1
  • InChIKey: DPNNNPAKRZOSMO-UHFFFAOYSA-K
  • Mol. Mass: 558.68
  • ALogP: Missing data
  • ChEMBL Molecule:
    gadoteridol  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$5.9860 - $46.4400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

gadolinium 1,4,7-tris(carboxymethyl)-10-(2'-hydroxypropyl)-1,4,7,10-tetraazacyclododecane | gadolinium 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane | gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate | gadolinium hp-do3a | gadolinium-hp-do3a | gadolinium-hp-do 3a | gadoteridol | gadoteridolum | gd(do3a) | gd-hp-d03a | gdhpdo3a | gd-hpdo3a | gd-hp-do3a | gd-hp-do 3a | gd-hydroxypropyl-d03a | prohance | prohance multipack | sq 32692 | sq 32,692 | sq-32692

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (1)


 

Diagnostic Imaging (approved 1992)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Astrocytoma (Phase 1)

Brain Diseases (Phase 4)

Brain Neoplasms (Phase 3)

Central Nervous System Diseases (Phase 3)

Cognition (Phase 4)

Contrast Media (Phase 4)

Diagnostic Imaging (Phase 3)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Magnetic Resonance Imaging (Phase 3)

Motor Activity (Phase 4)

Multiple Sclerosis (Early Phase 1)

Multiple Sclerosis, Chronic Progressive (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue